Business · 19/10/2026

Actinium Pharmaceuticals to showcase ATNM-400's first-in-human clinical data on prostate cancer and preclinical results on lung cancer supporting pan-tumor potential today at EANM 2026

First in human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMA Preclinical presentation to feature ATNM-400 st...